A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Ibrutinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 24 Nov 2021 Primary endpoint "MTD determination" was removed from the protocol. Changes made to treatment arms.
- 01 Aug 2020 Results of phase II part of the study (n=59), published in the Hematological Oncology.
- 04 Apr 2019 Status changed from active, no longer recruiting to completed.